TFS Capital’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

TFS Capital’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-118,230	Closed	-$2.14M	–	1279
2015 Q1	$2.14M	Sell	118,230 -11,344	-9%	-$255K	0.21%	121
2014 Q4	$3.06M	Buy	+129,574	New	+$3M	0.29%	87
2014 Q2	–	Sell	-135,107	Closed	-$4.59M	–	1621
2014 Q1	$4.59M	Buy	+135,107	New	+$4.62M	0.3%	45

Other funds holding CTIC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

TFS Capital's CTIC Position: Q2 2015 in Review

TFS Capital sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2015, closing a stake of 118,230 shares — an estimated $2.14M sold.

TFS Capital first reported a position in CTIC in Q1 2014 and held it in 3 quarters. The position peaked at $4.59M in Q1 2014. 95 funds tracked by Wall St. Rank hold CTIC as of Q2 2015.

TFS Capital reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2015 after selling out during the quarter.
TFS Capital sold 118,230 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2015, an estimated $2.14M.
TFS Capital first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2014 and held it in 3 quarters.
TFS Capital's CTI BioPharma Corp. (DE) Common Stock position peaked at $4.59M in Q1 2014.
95 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2015.

Based on TFS Capital's 13F filing for Q2 2015, filed 5 Aug 2015.